---
title: "Immutep Reaches 50% Enrollment Milestone in Global Phase III TACTI-004 Trial for First-Line NSCLC"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275047348.md"
datetime: "2026-02-05T23:53:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275047348.md)
  - [en](https://longbridge.com/en/news/275047348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275047348.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275047348.md) | [繁體中文](https://longbridge.com/zh-HK/news/275047348.md)


# Immutep Reaches 50% Enrollment Milestone in Global Phase III TACTI-004 Trial for First-Line NSCLC

Immutep Ltd. announced that it has achieved 50% enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial for first-line treatment of advanced/metastatic non-small cell lung cancer (1L NSCLC). The trial is evaluating the combination of eftilagimod alfa (efti) with KEYTRUDA® (pembrolizumab) and chemotherapy. To date, 378 patients have been enrolled globally, with more than 140 clinical sites activated across 27 countries. A futility analysis is scheduled for the first quarter of 2026, and completion of patient enrolment is expected in the third quarter of 2026. Results from the study have not yet been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相关股票

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Immutep (IMMP.US)](https://longbridge.com/zh-CN/quote/IMMP.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Immutep Ltd (IMM.AU)](https://longbridge.com/zh-CN/quote/IMM.AU.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)

## 相关资讯与研究

- [Immutep halts late-stage trial for lead asset after efficacy analysis](https://longbridge.com/zh-CN/news/279032924.md)
- [Immutep Discontinues Phase III Trial Of Eftilagimod Alfa In First-Line NSCLC; Stock Drops](https://longbridge.com/zh-CN/news/279000682.md)
- [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/zh-CN/news/278776483.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/zh-CN/news/278566951.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/zh-CN/news/278448836.md)